Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level

Detection of Possible Role of CD11a in Pathogenesis of Primary Immune Thrombocytopenia and Effect of Immunosuppressive Therapy on Its Level

1. The purpose of this study is to investigate the expression of CD11a on subpopulation of lymphocytes and compared its expression between ITP patients and healthy controls and explores its possible role in the pathogenesis of ITP.
2. this may help in decision to use inhibitors (have been developed to block ICAM-1/LFA-1 interactions,) as a line of treatment for ITP and some of these molecules have reached clinical trials.
3. to study if there is correlation between level of CD11a and severity of bleeding at presentation (estimated by bleeding score defined by British Journal of Haematology 2007 and platelet count)
4. to study effect of immunosuppressive treatment on the level of CD11a by evaluating levels of CD11a after response to treatment.

Study Overview

• Status: Completed
• Conditions: Idiopathic Thrombocytopenic Purpura

Detailed Description

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by low platelet counts with or without mucocutaneous bleeding (McMillan 2007).

Like the majority of autoimmune diseases, ITP is an organ-specific disease and abnormalities in the regulation of immune system have been shown to play an important role in the initiation and/or perpetuation of the disease Autoantibodies reacting against platelet glycoproteins can mediate platelet destruction by the monocyte-macrophage system as well as suppress megakaryocyte proliferation and maturation Although auto reactive B lymphocytes secreting antiplatelet antibodies are considered as the main defect, substantial evidence suggests that a generalized dysfunction of auto reactive T cells is the critical immunopathological cause of ITP and the antiplatelet autoantibodies are under the control of T cells and the cytokines they produce Lymphocyte function associated antigen-1 (LFA-1) belonging to the integrin family is composed of the alpha chain CD11a and beta chain CD18 heterologous dimers , and expressed on the surface of T lymphocytes, B lymphocytes, monocytes, macrophages and neutrophils. Its major ligand, intercellular adhesion molecule-1(ICAM-1) , belongs to the immunoglobulin superfamily, distributed on the surface of antigen- presenting cells (APCs) The combination of LFA-1 and ICAM-1 can provide coordinated stimulus signal and promote lymphocyte activation, proliferation and differentiation. In the interaction of T cells with antigen- presenting cells (APCs), LFA-1 and its adaptor ICAM-1 directly participate in the formation of immunological synapse that promotes costimulatory function, leading to increased T cell proliferation and cytotoxicity CD11a is critical for lymphocyte entry into the lymph nodes and normal development of hematopoietic intermediates The disruption of LFA-1 activity strongly affects the stability of immune interface .

The expression of ICAM-1 and LFA-1 is significantly higher on lymphoid cells and vascular endothelial cells in rheumatoid arthritis (RA), indicating that the combination of LFA-1 and ICAM-1 may play an important role in the progression of RA The excessive expression of LFA-1 can induce the formation of auto-reactive T cells, resulting in lupus disease in mice. By using LFA-1 monoclonal antibodies in lupus mice the production of autoantibodies could be reduced, the development of autoimmune reaction stopped, and the symptoms of lupus nephritis alleviated. Therefore, LFA-1 may play an important role in the pathogenesis of systemic lupus erythematosus.

In ITP patients CD11a could facilitate the survival of CD19+ B cells and promote antibody-mediated platelets destruction .Therefore, blocking ICAM-1/LFA-1 interaction can suppress T-cell activation in autoimmune diseases. Many types of inhibitors (i.e. antibodies, peptides, small molecules) have been developed to block ICAM-1/LFA-1 interactions, and some of these molecules have reached clinical trials.

• Study Type: Observational
• Enrollment (Actual): 80

Contacts and Locations

Study Locations

• Egypt
  • Assiut, Egypt
    • Mona

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

people with newely diagnosed primary ITP and healthy control

Description

Inclusion Criteria:

• newly diagnosed primary immune thrombocytopenic patients

Exclusion Criteria:

• We will exclude patients with any other possible cause of thrombocytopenia either immune or non immune as:
• Patients with diabetes
• HCV
• other autoimmune disease (as SLE or RA)
• Chronic Liver or kidney disease

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort
cases of newly diagnosed ITP; no intervention
cases of ITP after responding to treatment; no intervention
healthy subjects; no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
detection of possible role of CD11a in pathogenesis of ITP	assaying of CD11a in patients and healthy individual	1 year
detection of effect of immunosuppressive therapy on the level of CD11a in patients of ITP	to study effect of immunosuppressive treatment on the level of CD11a by evaluating levels of CD11a after response to treatment.to detect possible role of CD11a-ICAM1 blocker in treatment of ITP	1 year

Collaborators and Investigators

• Sponsor: Assiut University
• Investigators: Study Director: Howwaida AH Nafady, Prof., Assiut University

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2019
• Primary Completion (Actual): May 1, 2020
• Study Completion (Actual): January 1, 2021

Study Registration Dates

• First Submitted: February 26, 2019
• First Submitted That Met QC Criteria: March 4, 2019
• First Posted (Actual): March 6, 2019

Study Record Updates

• Last Update Posted (Actual): January 13, 2021
• Last Update Submitted That Met QC Criteria: January 12, 2021
• Last Verified: January 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Immune System Diseases; Autoimmune Diseases; Hematologic Diseases; Hemorrhage; Hemorrhagic Disorders; Blood Coagulation Disorders; Skin Manifestations; Thrombocytopenia; Blood Platelet Disorders; Thrombotic Microangiopathies; Purpura; Purpura, Thrombocytopenic; Purpura, Thrombocytopenic, Idiopathic
• Other Study ID Numbers: CD11a in ITP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No